What is Centese?
Centese operates at the intersection of medical engineering and clinical efficiency, primarily through its flagship Thoraguard system. Designed specifically for the rigors of cardiothoracic surgery, the platform replaces legacy drainage methods with an automated, data-rich solution. By providing real-time monitoring and automated chest tube clearance, Centese addresses the systemic inefficiencies that often plague post-operative recovery in ICU and critical care settings.
The company's value proposition is rooted in the reduction of hospital costs and the improvement of patient safety metrics. By digitizing the drainage process, Centese empowers clinical teams to make informed, rapid decisions, thereby optimizing workflow and reducing the duration of patient stays. This technological shift represents a critical evolution in how thoracic care is managed, moving away from manual observation toward intelligent, automated oversight.
How much funding has Centese raised?
Centese has raised a total of $15.3M across 2 funding rounds:
Series B
$15M
Stock/Share Issuance
$250K
Series B (2023): $15M with participation from MedTech Venture Partners
Stock/Share Issuance (2026): $250K, investors not publicly disclosed
Key Investors in Centese
MedTech Venture Partners
MedTech Venture Partners is a specialized investment firm dedicated to the medical technology sector, providing both capital and strategic guidance to healthcare innovators.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Centese?
With the recent influx of capital, Centese is expected to prioritize the expansion of its commercial reach and the further refinement of its clinical data analytics suite. The company is likely to focus on deepening its penetration within major hospital networks, where the demand for automated, high-reliability surgical tools is increasing. Furthermore, the strategic deployment of these funds will likely support ongoing research and development efforts aimed at broadening the application of the Thoraguard system across diverse surgical disciplines.
As Centese continues to scale, the integration of its data-monitoring capabilities into broader hospital information systems will be a key indicator of its long-term market dominance. The firm is well-positioned to capitalize on the growing trend of value-based care, where clinical outcomes and cost-efficiency are the primary drivers of procurement decisions in the medical technology sector.
